HCMT
CASC

Highland Capital Management (Texas)’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Highland Capital Management (Texas)’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-136,224
Closed -$1.33M – 346
2015
Q1 		$1.33M Buy
136,224
+41,789
+44% +$410K 0.03% 195
2014
Q4 		$1.08M Sell
94,435
-114,713
-55% -$1.25M 0.04% 158
2014
Q3 		$2.41M Buy
+209,148
New +$3.19M 0.09% 142

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highland Capital Management (Texas)'s CASC Position: Q2 2015 in Review

Highland Capital Management (Texas) sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2015, closing a stake of 136,224 shares — an estimated $1.33M sold.

Highland Capital Management (Texas) first reported a position in CASC in Q3 2014 and held it in 3 quarters. The position peaked at $2.41M in Q3 2014. 100 funds tracked by Wall St. Rank hold CASC as of Q2 2015.

  • Highland Capital Management (Texas) reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Highland Capital Management (Texas) sold 136,224 Cascadian Therapeutics, Inc. shares in Q2 2015, an estimated $1.33M.
  • Highland Capital Management (Texas) first reported a position in Cascadian Therapeutics, Inc. in Q3 2014 and held it in 3 quarters.
  • Highland Capital Management (Texas)'s Cascadian Therapeutics, Inc. position peaked at $2.41M in Q3 2014.
  • 100 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2015.

Based on Highland Capital Management (Texas)'s 13F filing for Q2 2015, filed 14 Aug 2015.